<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557020</url>
  </required_header>
  <id_info>
    <org_study_id>NPC2020-001</org_study_id>
    <nct_id>NCT04557020</nct_id>
  </id_info>
  <brief_title>Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma</brief_title>
  <official_title>Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Provincial Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial comparing neoadjuvant and adjuvant PD-1 inhibitor&#xD;
      Toripalimab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant&#xD;
      chemotherapy and concurrent chemoradiotherapy alone in high-risk nasopharyngeal carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 25, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>3 year</time_frame>
    <description>From date of randomization to date of first documentation of progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 year</time_frame>
    <description>From date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>3 year</time_frame>
    <description>From date of randomization to date of first documentation of distant metastases or until the date of the last followup visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival (LRRFS)</measure>
    <time_frame>3 year</time_frame>
    <description>From date of randomization to date of first documentation of locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>within 3 weeks after neoadjuvant treatment and 3 months after concurrent chemoradiotherapy</time_frame>
    <description>Either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) from the National Cancer Institute (NCI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>3 year</time_frame>
    <description>Treatment-related AEs (trAEs) and immune-related AEs (irAEs) according to the Common Terminology Criteria for Adverse Events, version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 antibody</intervention_name>
    <description>neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis Platinum</intervention_name>
    <description>neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cis Platinum</intervention_name>
    <description>concurrent chemoradiotherapy: 100mg/m2 in day 1, 22, and 43 during IMRT</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma&#xD;
&#xD;
          2. Clinical staged as T4 or N3 （according to the 8th AJCC edition）&#xD;
&#xD;
          3. No evidence of distant metastasis (M0)&#xD;
&#xD;
          4. Male and no pregnant female&#xD;
&#xD;
          5. ECOG (Eastern Cooperative OncologyGroup) scale 0-1&#xD;
&#xD;
          6. WBC ≥ 4×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L&#xD;
&#xD;
          7. Normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 2.0×ULN)&#xD;
&#xD;
          8. Normal renal function test ( creatinine clearance ≥60 ml/min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent or distant metastatic disease.&#xD;
&#xD;
          2. History of malignant tumors (except cured basal cell carcinoma or uterine cervical&#xD;
             carcinoma in situ) within the last 5 years.&#xD;
&#xD;
          3. History of radiotherapy or chemotherapy.&#xD;
&#xD;
          4. History of immunodeficiency disease&#xD;
&#xD;
          5. History of organ transplantation&#xD;
&#xD;
          6. Presence of life-threatening illness&#xD;
&#xD;
          7. Uncontrolled hypercalcemia&#xD;
&#xD;
          8. Severe uncontrolled medical conditions or active infectious diseases&#xD;
&#xD;
          9. Use of large doses of glucocorticoids, anti-cancer monoclonal antibodies, or other&#xD;
             immunosuppressive agents within 4 weeks.&#xD;
&#xD;
         10. Pregnant or breastfeeding female&#xD;
&#xD;
         11. Emotional disturbance or mental illness&#xD;
&#xD;
         12. Refusal or inability to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingao Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangxi Cancer Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingao Li</last_name>
    <phone>86-791-88300252</phone>
    <email>lijingao@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ganzhou Cancer Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaojun Zhong, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Xiaojun Zhong, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianwu Ding, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Jianwu Ding, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shangrao People's Hospital</name>
      <address>
        <city>Shangrao</city>
        <state>Jiangxi</state>
        <zip>334120</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kairong Huang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Kairong Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

